This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 23, 2012 /PRNewswire/ -- Escalon Medical Corp.'s (Nasdaq Market: ESMC) subsidiary, Sonomed Escalon™ announced the release of its new iPad App for the AXIS™ Image Management System at the recent World Ophthalmology Congress held
February 16-20 in
Abu Dhabi, UAE.
Matthew Carnevale, Chief Technical Officer, stated that "the AXIS iPad App is an industry first in ophthalmic diagnostic imaging management, and provides an entirely new level of flexibility and power. A clinician can now view all of their ophthalmic diagnostic images from anywhere at any time on their iPad, including slice-by-slice review of OCT images, fundus images, ultrasound, visual fields and more." The AXIS iPad App was first displayed pre-release at the American Academy of Ophthalmology meeting held
October 22-25 2011 in Orlando FL. In addition, AXIS and the iPad App were on display in the Heidelberg Engineering booth to showcase the combination of AXIS and the Heidelberg Spectralis OCT/SLO system. Mr. Carnevale continued, "The response to the powerful combination of the AXIS iPad App and the Heidelberg Spectralis was overwhelming."
AXIS is a web-based image management system accessible from any standard Internet browser that manages all images from any ophthalmic diagnostic device within a single database. The AXIS iPad App seamlessly integrates with AXIS to provide image review capabilities within an efficient and portable platform.
The AXIS iPad App is now available in the Apple App Store. Sonomed Escalon™ is the new combined ophthalmic products brand of Escalon Medical Corp.
Founded in 1987, the Company (
www.escalonmed.com) develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company 's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in
Wayne, Pennsylvania and operations in Long Island,
New Berlin, Wisconsin,
Miami, Florida and Barrow-in-Furness, U.K.
Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to: